Xcorporeal, Inc. (XCRP) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerXcorporeal, Inc. (XCRP) trades at $0.0001. Xcorporeal, Inc. is currently in the process of liquidation and dissolution, having transferred its assets to a liquidating trust. Previously, it was a medical device company focused on developing extra-corporeal platform technology. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for XCRP: XCRP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Xcorporeal, Inc. (XCRP) Healthcare & Pipeline Overview
Xcorporeal, Inc., currently undergoing liquidation and dissolution, formerly operated as a medical device company. It focused on developing extra-corporeal platform technology for organ replacement. The company transferred its assets to a liquidating trust in 2010 and is no longer actively developing medical devices.
What Is the Investment Thesis for XCRP?
Xcorporeal, Inc. presents a unique situation for investors, as the company is currently undergoing liquidation. The primary value driver is the assets held within the Xcorporeal, Inc. Liquidating Trust and the potential for distribution to shareholders after all liabilities are settled. Investors should carefully examine the trust documents and financial reports, if available, to assess the potential recovery value. Given the company's state of liquidation since 2010, there are no growth catalysts related to its former medical device operations. The investment thesis hinges entirely on the efficient and timely liquidation of assets and the distribution of proceeds to shareholders. The high beta of 58.42 reflects the speculative nature of the stock.
Based on FMP financials and quantitative analysis
XCRP Key Highlights
Xcorporeal, Inc. is currently in liquidation, with all assets transferred to the Xcorporeal, Inc. Liquidating Trust.
- The company's market capitalization is $0.00B, reflecting its state of liquidation.
- Free cash flow is negative ($-0.00B), indicative of the company's lack of ongoing operations.
- The company does not offer a dividend, as it is in liquidation.
- The beta of 58.42 indicates extremely high volatility and speculative interest.
Who Are XCRP's Competitors?
XCRP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.84 | -1.12% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.10 | +0.75% | $5.63M | 33 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.75 | +0.91% | $31.7M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | +4.33% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.98 | +1.02% | $49.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.73 | +1.91% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.75 | +2.74% | $82.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.55 | +2.00% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XCRP's Key Strengths?
Previously held proprietary extra-corporeal platform technology.
- Experienced management team in medical device development (prior to liquidation).
- Established Xcorporeal, Inc. Liquidating Trust to manage asset distribution.
- Potential for asset recovery and distribution to shareholders.
What Are XCRP's Weaknesses?
Company is in liquidation and no longer operating.
- No ongoing revenue generation or product development.
- Uncertainty regarding the value of assets held by the liquidating trust.
- High beta indicates significant volatility and speculative interest.
What Are the Key Risks for XCRP?
Uncertainty regarding the value of assets held by the liquidating trust.
- Unforeseen liabilities or claims against the trust that could reduce asset distribution.
- Delays in the liquidation process due to legal or administrative hurdles.
- Decline in value of assets held by the trust due to market conditions or other factors.
- Limited liquidity and difficulty in trading XCRP shares on the OTC market.
What Are XCRP's Competitive Advantages?
- Previously, Xcorporeal, Inc. sought to establish a competitive advantage through its proprietary extra-corporeal platform technology.
- The company aimed to secure patents and intellectual property rights to protect its innovations.
- However, with the company in liquidation, any prior competitive advantages are no longer relevant.
What Does XCRP Do?
Xcorporeal, Inc., founded in 2001 and based in Lake Forest, California, is currently in the process of liquidation and dissolution. This decision was formalized on February 4, 2010, when the board of directors adopted a plan to liquidate the company. As part of this process, Xcorporeal, Inc. formed the Xcorporeal, Inc. Liquidating Trust and transferred all of its assets to this trust. The purpose of this transfer was to facilitate the completion of the liquidation and dissolution of the company. Prior to its liquidation, Xcorporeal, Inc. operated as a medical device company. Its primary focus was the development of an extra-corporeal platform technology. This technology was intended for use in devices designed to replace the function of various human organs. The company's efforts were centered around creating innovative solutions in the field of organ replacement through advanced medical devices. With the transfer of assets to the liquidating trust, Xcorporeal, Inc. ceased its operations as a medical device company and is now solely focused on completing the liquidation process.
What Products and Services Does XCRP Offer?
- Xcorporeal, Inc. is currently undergoing liquidation and dissolution.
- The company previously developed extra-corporeal platform technology.
- Their technology was intended for use in devices to replace the function of various human organs.
- All assets have been transferred to the Xcorporeal, Inc. Liquidating Trust.
- The trust is responsible for completing the liquidation process.
- The company is no longer actively developing or manufacturing medical devices.
How Does XCRP Make Money?
- Previously, Xcorporeal, Inc. aimed to generate revenue through the sale of medical devices utilizing its extra-corporeal platform technology.
- The company sought to partner with healthcare providers and institutions to integrate its devices into their treatment protocols.
- Currently, the business model is focused solely on liquidating assets and distributing proceeds to shareholders after settling liabilities.
What Industry Does XCRP Operate In?
Xcorporeal, Inc. previously operated in the medical device industry, a sector characterized by innovation, regulatory scrutiny, and significant capital investment. The industry is driven by advancements in technology and the increasing demand for improved healthcare solutions. Companies in this sector face intense competition from established players and emerging startups. Given Xcorporeal's liquidation status since 2010, it is no longer a participant in the competitive landscape. The medical device industry continues to grow, driven by factors such as an aging population and increasing prevalence of chronic diseases.
Who Are XCRP's Key Customers?
- Historically, Xcorporeal, Inc. targeted hospitals and medical centers as primary customers.
- The company aimed to serve patients requiring organ replacement or support through its medical devices.
- Currently, the company has no active customers as it is in liquidation.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Xcorporeal, Inc. operates in the Medical Devices industry within the Healthcare sector. It is headquartered in Lake Forest, United States.
XCRP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
XCRP Latest News
No recent news available for XCRP.
XCRP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for XCRP.
Price Targets
Wall Street price target analysis for XCRP.
XCRP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for XCRP; grades run from A+ (80-100) to F (below 30).
XCRP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing companies that do not meet the minimum qualifications for OTCQX, OTCQB, or Pink tiers. Companies in this tier may be distressed, in bankruptcy, or have limited or no public information available. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ. These securities are often highly speculative and may be difficult to trade.
- OTC Tier: OTC Other
- Limited or no financial disclosure requirements.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- High risk of delisting or suspension of trading.
- Limited liquidity and difficulty in buying or selling shares.
- Uncertainty regarding the value of assets held by the liquidating trust.
- Review the Xcorporeal, Inc. Liquidating Trust documents.
- Assess the value of assets held by the liquidating trust.
- Evaluate potential liabilities and claims against the trust.
- Monitor updates on the liquidation process.
- Consider the potential tax implications of asset distribution.
- Consult with a financial advisor regarding the risks of investing in OTC Other stocks.
- Formation of a liquidating trust suggests a structured approach to asset distribution.
- Previous operation as a medical device company indicates a history of business activity.
- Listing on the OTC market, even in the Other tier, provides some level of public visibility.
- Transfer of assets to the trust for the purpose of liquidation and dissolution.
Xcorporeal, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for XCRP?
The primary risks for XCRP are related to its liquidation status. These include uncertainty regarding the value of assets held by the Xcorporeal, Inc. Liquidating Trust, potential liabilities or claims against the trust, delays in the liquidation process, and limited liquidity in trading XCRP shares on the OTC market.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be limited due to the company's liquidation status.
- The value of assets held by the Xcorporeal, Inc. Liquidating Trust is uncertain and subject to change.
- Investment in XCRP carries significant risks due to its OTC Other listing and liquidation status.